



ASX Announcement

21st July 2020

Notice of Allowance for Key US Exenatide Patent

Invex Therapeutics Ltd (Invex, ASX: IXC, or the Company) today announced the United States Patent and Trademark Office has issued a notice of allowance for Invex's patent application 15/504,399, titled "Elevated Intracranial Pressure Treatment". This patent covers the use of GLP-1 receptor agonists, including Exenatide, in reducing elevated intracranial pressure (ICP) in a given subject. Elevated ICP is associated with a range of diseases including Idiopathic Intracranial Hypertension (IIH) and is a secondary complication in other brain diseases including traumatic brain injury, tumours and meningitis.

Invex recently demonstrated a strong statistical and clinical benefit of Exenatide in reducing ICP in IIH and additionally in several clinically important endpoints including improvement in visual acuity and a reduction in monthly headache days.

All intellectual property has been previously assigned from the University of Birmingham directly to Invex in exchange for a small ownership stake in the Company.

Dr Jason Loveridge, Chairman of Invex said "One of our corporate strategies is to maximise the value of our Exenatide assets through multiple layers of protection utilising both regulatory and patent mechanisms. Our granted orphan drug designation for Exenatide in IIH in both the US and Europe provides us seven and ten years market exclusivity, respectively. The allowance of this key US patent, which provides protection until at least August 2035, will be beneficial in future partnering discussions as we seek to commence our single Phase III registration trial in Europe and the US following the recent capital raise."

This release dated 21st July has been authorised for lodgement to the ASX by the Board of Directors of Invex Therapeutics and lodged by Narelle Warren, Company Secretary.

ENDS

For more information, please contact:

Investors

Dr Thomas Duthy
Nemean Group
tduthy@nemean.com.au
+61 402 493 727

Media

Margie Livingston
Ignite Communications
margie@ignitecommunications.com.au
+61 438 661 131

About Invex Therapeutics Ltd

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin™. www.invextherapeutics.com.

About Idiopathic Intracranial Hypertension (IIH)

IIH features severely raised intracranial pressure which causes disabling daily headaches and can compress the optic nerve, causing permanent vision loss in 25% of those affected. The usual age of onset is 20-30 years, and it is most common in women who are obese. IIH is a rapidly growing orphan indication: its incidence has increased by more than 350% in the last 10 years.

About Exenatide

Exenatide is a small peptide and a synthetic version of the GLP-1 agonist exendin-4, which received approval in the US and Europe for the treatment of type 2 diabetes in 2005 and 2006 respectively. Professor Alexandra Sinclair's research showed that GLP-1 receptors are expressed in the choroid plexus in the brain and that Exenatide can bind to these receptors and reduce secretion of cerebrospinal fluid. Current Exenatide dosage forms are not optimised for IIH.